SiNtx Technologies Inc. Expands Product Portfolio with OsseoSculpt and a New Private‑Label Agreement
SiNtx Technologies Inc. (NASDAQ: SINT) announced the launch of OsseoSculpt, an advanced biologic designed to enhance bone healing, on 3 November 2025. The product is specifically intended for use with the company’s SINAPTIC Foot & Ankle Osteotomy Wedge System, a device that supports surgical correction of foot and ankle deformities.
Product Details
- OsseoSculpt is a biologic product that leverages the company’s proprietary silicon nitride technology platform.
- The biologic is engineered to promote osteogenesis and improve fusion outcomes in orthopedic procedures.
- It is marketed as a complement to the SINAPTIC Foot & Ankle Osteotomy Wedge System, providing a targeted approach to enhance bone integration.
Private‑Label Agreement
On the same day, SiNtx reported that it had secured a private‑label contract for a bone‑healing biologic. The agreement involves the manufacturing and supply of the biologic under the terms of the contract, allowing the partner to market the product under its own brand name. The arrangement underscores the company’s strategy to expand its market presence through collaborative partnerships.
Market Context
SiNtx operates within the Health Care Equipment & Supplies sector and serves the United States market. The company’s financial profile as of 30 October 2025 shows a close price of USD 3.19, a 52‑week high of USD 8.596 (as of 24 November 2024) and a 52‑week low of USD 1.71 (as of 15 April 2025). With a market capitalization of approximately USD 11.44 million, the company’s price‑earnings ratio stands at –0.44, reflecting its current operating losses.
The introduction of OsseoSculpt and the private‑label agreement represent significant steps for SiNtx, potentially increasing revenue streams and enhancing its position in the competitive orthopedic device market.
